What is Tonix Pharmaceuticals Holding Quick Ratio?
Tonix Pharmaceuticals HoldingTNXP +10.54%41 Quick Ratio is 6.83 as of Mar. 2026, which is 23% below its 10-year median of 8.86. GuruFocus rates TNXP with a GF Score™ of 41/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Tonix Pharmaceuticals Holding ranks better than 68.65% on this metric.
Tonix Pharmaceuticals Holding has a quick ratio of 6.83. It generally indicates good short-term financial strength.
The historical rank and industry rank for Tonix Pharmaceuticals Holding's Quick Ratio or its related term are showing as below:
TNXP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.72 Med: 8.86 Max: 28.73
Current: 6.83
During the past 13 years, Tonix Pharmaceuticals Holding's highest Quick Ratio was 28.73. The lowest was 0.72. And the median was 8.86.
TNXP's Quick Ratio is ranked better than 68.65% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs TNXP: 6.83
Tonix Pharmaceuticals Holding (NAS:TNXP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Tonix Pharmaceuticals Holding Quick Ratio Related Terms
Tonix Pharmaceuticals Holding Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tonix Pharmaceuticals Holding Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Tonix Pharmaceuticals Holding's Quick Ratio falls into.
Tonix Pharmaceuticals Holding Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tonix Pharmaceuticals Holding (TNXP) has a Quick Ratio of 6.83 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tonix Pharmaceuticals Holding and its competitors. This is 23% below median its historical median of 8.86. Over the past decade, Tonix Pharmaceuticals Holding's Quick Ratio has ranged from 0.72 to 28.73. According to the industry distribution chart, Tonix Pharmaceuticals Holding ranks #443 out of 1413 companies in the Biotechnology industry, placing it in the top 31.4%.
Is Tonix Pharmaceuticals Holding's Quick Ratio too high?
Tonix Pharmaceuticals Holding's current Quick Ratio of 6.83 is 23% below median its 10-year median of 8.86. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 28.73. The Biotechnology industry median Quick Ratio is 3.60. Tonix Pharmaceuticals Holding's value of 6.83 is 89.7% above this industry median. Based on the distribution chart, Tonix Pharmaceuticals Holding ranks #443 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Quick Ratio compare to UNCY and ENLV?
According to the Biotechnology industry distribution chart, Tonix Pharmaceuticals Holding ranks #443 out of 1413 companies for Quick Ratio. This puts Tonix Pharmaceuticals Holding in the upper half of its industry. The industry median Quick Ratio is 3.60. Tonix Pharmaceuticals Holding's value of 6.83 is 89.7% above this benchmark. Historically, Tonix Pharmaceuticals Holding's own Quick Ratio has ranged from 0.72 to 28.73 over the past decade. While the company's 10-year median is 8.86 vs. the industry median of 3.60, Tonix Pharmaceuticals Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tonix Pharmaceuticals Holding's current Quick Ratio of 6.83 is 89.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tonix Pharmaceuticals Holding and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tonix Pharmaceuticals Holding's current Quick Ratio is 6.83, which is 23% below median its own 10-year median of 8.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $13.11 — trading 649.1% above its estimated fair value. The current Quick Ratio is 6.83, which is 23% below median its 10-year median of 8.86 and 89.7% above the Biotechnology industry median of 3.60. Tonix Pharmaceuticals Holding's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current Quick Ratio is 6.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued.
The current stock price of $13.11 is trading 649.1% above its estimated GF Value™ of $1.75.
GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.
Key valuation signals for TNXP:
Quick Ratio: 6.83 (23% below median its 10-year median of 8.86)
GF Value™: $1.75 vs. price of $13.11 (649.1% above fair value)
Industry Position: 89.7% above the Biotechnology median (#443 of 1413)
No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tonix Pharmaceuticals Holding Business Description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
41GF Score
Get the complete analysis for TNXP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNXP has been successfully added to your 
